Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;24(9):577–584. doi: 10.1002/clc.4960240903

Issues in the assessment of the safety and efficacy of tenecteplase (TNK‐tPA)

C Michael Gibson 1,✉, Susan J Marble 1
PMCID: PMC6655068  PMID: 11558838

Abstract

While thrombolytic agents have demonstrated improved mortality over the use of placebo, this has come at the expense of bleeding complications such as intracranial hemorrhage (ICH). Tenecteplase (TNK‐tPA) is a novel thrombolytic agent engineered to improve upon the ease of use and safety of alteplase (t‐PA). Given its longer half‐life, TNK‐tPA can be administered as a single bolus. The dosing of TNK‐tPA has been weight optimized to enhance both safety and efficacy outcomes. Weight‐optimized TNK‐tPA dosing requires body weight estimation, which may introduce the potential for medication error. However, data from TNK‐tPA clinical trials suggest that body weight estimates can err by up to 20 kg (44 lb) without an increased risk of ICH or death. Furthermore, the results of TNK‐tPA clinical trials showed that even at the highest weight‐optimized dosage of 50 mg, ICH rates were among the lowest reported in clinical trials of thrombolytics for acute myocardial infarction. in elderly female patients of low body weight, the use of weight‐optimized TNK‐tPA lowered the risk of ICH compared with the use of t‐PA, expanding the potential use of thrombolytics to this high‐risk patient population. Tenecteplase has demonstrated clinical equivalence to t‐PA, but with a wider therapeutic margin of safety.

Keywords: tenecteplase, weight‐optimized dosing, acute myocardial infarction, r‐PA, t‐PA, streptokinase

Full Text

The Full Text of this article is available as a PDF (826.6 KB).

References

  • 1. American Heart Association: Coronary Heart Disease and Angina Pectoris. Accessed October 2000. at http://www.americanheart.org
  • 2. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group : Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–322 [PubMed] [Google Scholar]
  • 3. Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simoons M, Armstrong PW, Topol EJ, Califf RM: Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction: The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 1997; 95: 2508–2516 [DOI] [PubMed] [Google Scholar]
  • 4. Gibson CM, Cannon CP, Murphy SA, Adgey JA, Schweiger MJ, Sequeira RF, Grollier G, Fox NL, Berioli S, Weaver WD, Van de Werf F, Braunwald E: Weight‐adjusted dosing of TNK‐tPA‐tissue plasminogen activator and its relation to angiographic outcomes in the Thrombolysis in Myocardial Infarction 10B trial. Am J Cardiol 1999; 84: 976–980 [DOI] [PubMed] [Google Scholar]
  • 5. Product data on file. Genentech, Inc. South San Francisco, Calif. [Google Scholar]
  • 6. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Peña L, Pater C, Ogez J, Etcheverry T, Botstein D, Bennett WF: A faster‐acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91 lpar;9): 3670–3674 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Sobel BE: The language of lysis: A proposal to standardize the nomenclature. J Am Coll Cardiol 1999; 34: 1226–1227 [DOI] [PubMed] [Google Scholar]
  • 8. Ross AM: New plasminogen activators: A clinical review. Clin Cardiol 1999; 22: 165–171 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Modi NB, Fox NL, Clow FW, Tanswell P, Cannon CP, Van de Werf F, Braunwald E: Pharmacokinetics and pharmacodynamics of tenecteplase: Results from a phase II study in patients with acute myocardial infarction. J Clin Pharmacol 2000; 40: 508–515 [DOI] [PubMed] [Google Scholar]
  • 10. TNKase™ (tenecteplase) full prescribing information In Physicians' Desk Reference, 55 edition, 1316–1318. Montvale, NJ: Medical Economics, 2001. [Google Scholar]
  • 11. Cannon CP, Gibson CM, McCabe CH, Adgey J, Schweiger MJ, Sequeira RF, Grollier G, Giugliano FP, Frey M, Mueller HS, Steingart RM, Weaver WD, Van de Werf F, Braunwald E: TNK‐tissue plasminogen activator compared with front‐loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial. Circulation 1998; 98: 2805–2814 [DOI] [PubMed] [Google Scholar]
  • 12. Cannon CP, McCabe CH, Gibson M, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E, TIMI 10A Investigators : TNK‐tPA‐tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose‐ranging trial. Circulation 1997; 95: 351–356 [DOI] [PubMed] [Google Scholar]
  • 13. Giugliano RP, Cannon CP, McCabe CH, Van de Werf F, Braunwald E: Lower dose heparin with thrombolysis is associated with lower rates of intracranial hemorrhage: Results from TIMI 10B and ASSENT 1 (abstr). Circulation 1997: 96; I–535 [Google Scholar]
  • 14. Gibson CM, Murphy SA, Rizzo MJ, Ryan KA, Marble SJ, McCabe CH, Cannon CP, Van de Werf F, Braunwald E: Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Circulation 1999; 99: 1945–1950 [DOI] [PubMed] [Google Scholar]
  • 15. Gibson CM, Murphy SA, Marble SJ, Barron HV, Cannon CP: Relation of epicardial blood flow and myocardial perfusion to long term outcomes 2 years following thrombolysis in acute MI: A TIMI 10b substudy (abstr). Circulation 2000; 102:II‐435 [DOI] [PubMed] [Google Scholar]
  • 16. Van de Werf FJ, Cannon CP, Luyten A, Houbracken K, McCabe CH, Berioli S, Bluhmki E, Sarelin H, Wang‐Clow F, Fox NL, Braunwald E: Safety assessment of a single bolus administration of TNK‐tPA‐tissue plasminogen activator in acute myocardial infarction: The ASSENT‐1 trial. Am Heart J 1999; 137: 786–791 [DOI] [PubMed] [Google Scholar]
  • 17. Van de Werf FJ: The ideal fibrinolytic: Can drug design improve clinical results? Eur Heart J 1999; 20: 1452–1458 [DOI] [PubMed] [Google Scholar]
  • 18. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT‐2) Investigators : Single‐bolus tenecteplase compared with front‐loaded alteplase in acute myocardial infarction: The ASSENT‐2 double‐blind randomised trial. Lancet 1999, 354: 716–722 [DOI] [PubMed] [Google Scholar]
  • 19. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators : A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118–1123 [DOI] [PubMed] [Google Scholar]
  • 20. TNKase™ (tenecteplase) prescribing information. Genentech, Inc, South San Francisco, Calif. Available at http:www.gene.com/products/tnkase/insert.html Accessed August 2000.
  • 21. Cannon CP: Thrombolysis medication errors: Benefits of bolus thrombolytic agents. Am J Cardiol 2000; 85: 17C–22C [DOI] [PubMed] [Google Scholar]
  • 22. Alexander J, Li X, Chin R: Safety and efficacy of 50 milligrams of TNK‐tPA in patients with acute myocardial infarction: Results from ASSENT‐2 (abstr). Circulation 2000; 102: 11–258 10880408 [Google Scholar]
  • 23. Gibson CM: The Impact of Fibrinolytic Dose on Outcome. Presented at the 16th International Symposium on Thrombolysis and Interventional Therapy in Acute Myocardial Infarction; November 11, 2000; New Orleans, La. (2000b)
  • 24. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver WD, White HD, Barbash GI, Van de Werf F, Aylward PE, Topol EJ, Califf RM: Stroke after thrombolysis: Mortality and functional outcomes in the GUSTO‐I trial. Circulation 1995; 92: 2811–2818 [DOI] [PubMed] [Google Scholar]
  • 25. Gurwitz JH, Gore JM, Goldberg RJ, Barron HV, Breen T, Rundle AC, Sloan MA, French W, Rogers WJ: Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Ann Intern Med 1998; 129: 597–604 [DOI] [PubMed] [Google Scholar]
  • 26. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett‐Connor E: Cardiovascular disease in women: A statement for healthcare professionals from the American Heart Association. Circulation 1997; 96: 2468–2482 [DOI] [PubMed] [Google Scholar]
  • 27. Barron HV, Fox NL, Berioloi S, Danays T, Li X, Wang‐Clow F, Van de Werf F: A comparison of intracranial hemorrhage rates in patients treated with rt‐PA and t‐PA‐TNK‐tPA: Impact of gender, age and low body weight (abstr). Circulation 1999; 100:I‐1 [Google Scholar]
  • 28. Lundergan CF, Reiner JS, McCarthy WF, Coyne KS, Califf RM, Ross AM: Clinical predictors of early infarct‐related artery patency following thrombolytic therapy: Importance of body weight, smoking history, infarct‐related artery and choice of thrombolytic regimen: The GUSTO‐I experience. J Am Coll Cardiol 1998; 32: 641–647 [DOI] [PubMed] [Google Scholar]
  • 29. Gibson CM: Weight‐Adjusted Dosing of Fibrinolytic Agents: The Good and the Bad. Presented at the George Washington University satellite symposium at the American Heart Association annual scientific program, November 11, 2000, New Orleans, La. (2000a)
  • 30. ISIS‐2 Collaborative Group . Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS‐2. Lancet 1988; 2: 349–360 [PubMed] [Google Scholar]
  • 31. INJECT Investigators : Randomised, double‐blind comparison of reteplase double‐bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 1995: 346: 329–336 [PubMed] [Google Scholar]
  • 32. Antman EM, Wilcox RG, Giugliano RP, McCabe CH, Foxley A, Pangerl A, Chew PH, Skene AM, Neuhaus KL, Braunwald E, and TIME II Investigators : Long‐term comparison of lanoteplase and alteplase in ST elevation myocardial infarction: 6 month followup in TIME II trial (abstr). Circulation 1999; 100: I–498 [Google Scholar]
  • 33. Klootwijk P, Langer A, Meij S, Green C, Veldkamp RF, Ross AM, Armstrong PW, Simoons ML: Non‐invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO‐I trial. Eur Heart J 1996; 17: 689–698 [DOI] [PubMed] [Google Scholar]
  • 34. Gore JM, Goldberg RJ: Optimal dosing of fibrinolytic agents: One size does not fit all (a CME white paper). Califon, New Jersey: Gardiner‐Caldwell Syner Med, 2000. [Google Scholar]
  • 35. Institute of Medicine: To Err is Human. Building a Safer Health System Washington DC: National Academy Press, 2000. Accessed at http://bob.nap/edu/html/to_err_is_human on June 5, 2000
  • 36. Brown G, Dodek P: An evaluation of empiric versus nomogram‐based dosing of heparin in an intensive care unit. Crit Care Med 1997; 25: 1534–1538 [DOI] [PubMed] [Google Scholar]
  • 37. Hassan WM, Flaker GC, Feutz C, Petroski F, Smith D: Improved anticoagulation with a weight‐adjusted heparin nomogram in patients with acute coronary syndromes: A randomized trial. J Thromb Thrombolysis 1995; 2: 245–249 [DOI] [PubMed] [Google Scholar]
  • 38. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel B, Russell RO, Smith EE III, Weaver WD: 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999; 100: 1016–1030 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES